Pds biotechnology reports inducement grant under nasdaq listing rule 5635(c)(4)

Princeton, n.j., dec. 06, 2024 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on december 3, 2024, pds biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with pds biotech and in accordance with nasdaq listing rule 5635(c)(4) and pds biotech's 2019 inducement plan, as amended, which was adopted on june 17, 2019, and provides for the granting of equity awards to new employees of pds biotech.
PDSB Ratings Summary
PDSB Quant Ranking